id stringclasses 6
values | disease_basin stringclasses 6
values | candidate_drug stringclasses 6
values | trial_outcome_summary stringclasses 6
values | failure_mode_evidence stringclasses 6
values | candidate_subgroup_axes stringclasses 6
values | responder_subgroup_signature stringclasses 6
values | non_responder_signature stringclasses 6
values | context_gates stringclasses 6
values | failure_mode_class stringclasses 6
values | salvage_hypothesis stringclasses 6
values | verification_plan stringclasses 6
values | notes stringclasses 6
values | constraints stringclasses 1
value | gold_checklist stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCSC-001 | post_viral_crash_basin | candidate immune modulator | Primary endpoint null; fatigue scale unchanged overall | Subgroup shows improved crash frequency | autonomic tone; PEM severity; viral reactivation markers | High PEM; high crash frequency; elevated reactivation markers | Low PEM; no crash pattern | pacing adherence; infection status | masked responder subgroup | Use in high-PEM subgroup with pacing protocol | Prospective enrichment; crash frequency endpoint | Signal masked by heterogeneity | Under 280 words. | subgroup+gate+class+plan |
FCSC-002 | metabolic_insulin_resistance_basin | candidate appetite agent | Weight loss modest overall; high dropout | Responder signal in high hunger phenotype | baseline hunger; sleep timing; GI tolerance | High hunger; stable sleep schedule; high adherence | Low hunger; irregular sleep; nausea prone | meal timing; dose titration | adherence-gated efficacy | Pair with meal timing protocol; slow titration | Stratify by hunger; track adherence and nausea | Context gate is tolerability | Under 280 words. | subgroup+gate+class+plan |
FCSC-003 | autoimmune_flare_basin | candidate cytokine inhibitor | Flare reduction not significant overall | Benefit only in high flare frequency subgroup | flare frequency; autoantibody load | Flares every 4 weeks; high autoantibody load | Flares rare; low autoantibody load | trigger seasonality; concurrent infections | frequency-gated efficacy | Enroll high-frequency patients; seasonal timing | Enriched trial; flare interval endpoint | Null hides subgroup benefit | Under 280 words. | subgroup+gate+class+plan |
FCSC-004 | hyperarousal_basin | candidate sleep agent | Sleep improves; daytime function worsens | Daytime impairment in slow metabolizers | metabolizer phenotype; baseline fatigue | Fast metabolizers; insomnia dominant | Slow metabolizers; baseline fatigue high | dose timing; occupational demands | toxicity in subgroup | Lower dose or earlier dosing in slow metabolizers | PK stratification; function endpoints | Context is metabolism and schedule | Under 280 words. | subgroup+gate+class+plan |
FCSC-005 | fibrotic_progression_basin | candidate antifibrotic | No significant slope change overall | Responder signal in early-stage imaging subgroup | disease stage; imaging pattern | Early-stage; mild imaging changes | Late-stage; advanced fibrosis | smoking exposure; adherence | stage-gated efficacy | Treat early-stage only with exposure removal | Stage-stratified trial; PFT slope | Early basin escapable | Under 280 words. | subgroup+gate+class+plan |
FCSC-006 | chronic_pain_sensitization_basin | candidate neuromodulator | Pain score improves; high discontinuation | Responders with high threat tone; nonresponders sedated | threat tone; sleep debt; comedication | High threat tone; low sedative burden | High sedative burden; falls risk | comedication; fall risk | contextual antagonism | Use only with sedative deprescribing | Run-in taper; falls endpoint | Context gate is sedation load | Under 280 words. | subgroup+gate+class+plan |
What this dataset tests
When a drug failed overall
but contains a responder niche.
Required outputs
- responder subgroup signature
- non-responder signature
- context gates
- failure mode class
- salvage hypothesis
- verification plan
Use case
Second layer of the Therapeutic Niche Construction Kit.
- Downloads last month
- 19